Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Birch Triterpenes→

Birch Triterpenes Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
1640971-03-4
Molecular formula
Not applicable (botanical mixture)
Molecular weight
Not applicable (botanical mixture) g/mol
Drug class
Topical birch bark triterpene-rich extractbotanical wound-treatment preparation
Mechanism of action
The mechanism by which birch triterpene extract improves epidermolysis bullosa wounds is not fully established. The formulation has been associated with support of wound healing and epithelialisation; do not assign a defined receptor or antiviral mechanism.
Indications / reported uses
  • Treatment of partial-thickness wounds associated with dystrophic and junctional epidermolysis bullosa in adults and paediatric patients aged 6 months and older under the US Filsuvez indication

Sources: US DailyMed — FILSUVEZ prescribing information · US FDA — FILSUVEZ product information · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Birch Triterpenes Environmental Risk Assessment (ERA) (the Birch Triterpenes ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.